“Our company is targeting the Tissue Micro-Environment (TiME), a key driving force of human diseases, as a fresh approach for making new medicines”
Legion (Lijien) Pharmaceuticals, is a new biotechnology company established in 2018 and located in the great city of Guangzhou that is strategically located in the Pearl River Delta of Southern China. The Company is the creation of GF Investments, Inc. and the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, two mainstay institutions in Guangzhou, representing a coordinated merging of expertise in capital investment and drug discovery sciences. With the merging of these two centers of excellence, Legion Pharmaceuticals on day one is poised to be both an early and late stage clinical biotechnology company, focused on developing and commercializing new medicines. Legion (Lijien) Pharmaceuticals differentiates itself from other biotechnology companies by its unique approach in targeting diseases that are mediated primarily by the Tissue Micro-Environment (TiME), which is a key driving force of many human diseases. Our TiME based drug discovery portfolio is unique and focused in three primary areas including Cancer, Inflammation and Pain (CIP), where the tissue microenvironment is known to play an important role in disease pathology.